Outset Medical
152 hedge funds and large institutions have $1.26B invested in Outset Medical in 2022 Q4 according to their latest regulatory filings, with 40 funds opening new positions, 44 increasing their positions, 44 reducing their positions, and 24 closing their positions.
3,263% more call options, than puts
Call options by funds: $9.99M | Put options by funds: $297K
67% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 24
66% more capital invested
Capital invested by funds: $760M → $1.26B (+$503M)
10% more funds holding
Funds holding: 138 → 152 (+14)
0.14% more ownership
Funds ownership: 6.63% → 6.77% (+0.14%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 44
Top Buyers
| 1 |
Barclays
London,
United Kingdom
|
+$8.27M |
| 2 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$8.01M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$6.52M |
| 4 |
D.E. Shaw & Co
New York
|
+$5.84M |
| 5 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
+$5.34M |
Top Sellers
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$11.6M |
| 2 |
Allspring Global Investments
Charlotte,
North Carolina
|
-$11.3M |
| 3 |
JP Morgan Chase
New York
|
-$9.94M |
| 4 |
PVI
Pura Vida Investments
New York
|
-$8.46M |
| 5 |
Jennison Associates
New York
|
-$6.59M |
OM Hedge Fund Activity: Q4 2022 in Review
152 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Outset Medical (OM) for Q4 2022, worth a combined $1.26B — up 66% from $760M a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new OM positions and 24 closed out — a net gain of 16 holders — while 44 added to existing stakes and 44 trimmed.
The largest buyer was Barclays, adding an estimated $8.27M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $11.6M sold.
- 152 institutional investors held Outset Medical (OM) as of Q4 2022, up from 138 in Q3 2022.
- Funds reported $1.26B of Outset Medical stock for Q4 2022, up 66% quarter-over-quarter.
- 40 funds opened new Outset Medical positions in Q4 2022 and 24 closed out, a net change of +16 holders.
- The largest Outset Medical buyer in Q4 2022 was Barclays, an estimated $8.27M added.
- The largest Outset Medical seller in Q4 2022 was PFM Health Sciences, an estimated $11.6M sold.
Based on aggregated 13F filings for Q4 2022.